chartexchange

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

The Motley Fool | Nov 10, 2026 1:50 PM EST

One stock that took a hard hit at the beginning of the trading week was that of specialty medical device maker NovoCure (NASDAQ:NVCR) . Investors sold out of the company aggressively after news that one of its products met its primary endpoint but fell short of key secondary endpoints in a crucial late-stage clinical trial. The shares initially swooned at a double-digit rate, but recovered, ending the day less than 6% lower. Does this make the unique healthcare stock a buy on the dip? That morning, NovoCure announced that it received a not approvable letter from the Food and Drug Administration (FDA) for its investigational device , Optune Mya. The company had submitted a premarket approval (PMA) application for the product to be accepted for the treatment of adults with non-small cell lung cancer that has metastasized to the brain and who have undergone targeted radiation for their brain tumors. Image source: Getty Images. Continue reading

Read original article